Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: aknahow who wrote (13762)	6/2/2000 12:03:00 PM
From: Robert K.	Read Replies (2) \| Respond to of 17367

Mycoprex deal? Hmm. A deal could probably happen at any time if xoma didnt care to haggle for terms. If you listen to the company, perhaps a deal is not close BUT>Castello smoked me on the neuprex deal. That said, anything is possible. This much I do know. Mycoprex holds a lot more potential than promise. Its novel, cidal, oral, safer, synergistic. Any single one is a big factor. Combined they rock. Jack understands this as does pharma. Genimune, one of my past favorites is back in vogue. I hear its stimulating unexpected interest. I hope xoma keeps it though. As long as we can deveolp it,>I prefer it stay in house. ING-1> I cant wait. Antiangio>a wild wild card. Standard K